Fundraising FoxEQT Life Sciences — 2025 Investments
8 investments dated 2025 · listed companies and verified rows first · show all
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersDementia Discovery FundM VenturesNovartis Venture FundPfizer Venture InvestmentsRA Capital+6 more
Atalanta is developing treatment options for intractable central nervous system diseases using RNA interference technology.
BiotechDeep TechHealthtechMedical Devices
Co-investorsF-Prime CapitalNovartis Venture FundRiverVest Venture PartnersSanofi Venturesabrdn plc
Cyted Health develops diagnostics for earlier and more accurate detection of esophageal disease, including its EndoSign capsule sponge cell collection device and molecular diagnostics, intended for clinicians screening for conditions such as Barrett's Esophagus and esophageal cancer.
BiotechHealthtechMedical Devices
Co-investorsAdvent Life Sciences
Kaleido offers a modular enterprise platform with pre-integrated products for tokenization, custody, digital assets, middleware, interoperability, and blockchain infrastructure.
Crypto & Web3Data & InfrastructureEnterprise Software
Steve Cerveny(Founder)inSophia Lopez(Founder)in
Co-investorsConsenSys MeshValor Capital GroupFlagship PioneeringInnovation IndustriesInvest-NLMenlo Ventures+1 more
Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees.
BiotechHealthtechMedical DevicesAliso Viejo, US
David Veino(President and CEO)Zach Stassen(Chief Financial Officer)Robert J. Centa(Chief Financial Officer)Jon J. Snyder(Director, President, Secretary and CEO)in
BoardJoyce Erony(Director)inWilliam Harrington(Director)in
Co-investorsAmzak HealthAPERTURE Venture PartnersCWRU Technology VenturesiSelect FundJobsOhio VenturesJumpstart Ventures+5 more
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in
Co-investorsBioMedPartnersJeito CapitalRoche Venture FundSofinnova PartnersEQTForbion+3 more
Perfuze develops medical devices for the treatment of acute ischemic stroke, focused on addressing unmet clinical needs in mechanical thrombectomy.
Deep TechHealthtechMedical DevicesGalway City, IE
Wayne Allen(Co-Founder, CEO, Director)inLiam Mullins(CTO and Co-founder)in
Co-investorsSeroba Life SciencesSV Health InvestorsBek VenturesEnterprise Ireland
Kaleido, a lightweight modular precision-dosing insulin pump.
Co-investorsInkefInnovation IndustriesForbionInvest-NLROM Utrecht Region
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.